Compare PYXS & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYXS | DOGZ |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | China |
| Employees | 56 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.2M | 153.5M |
| IPO Year | 2021 | 2017 |
| Metric | PYXS | DOGZ |
|---|---|---|
| Price | $2.75 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 534.1K | 29.3K |
| Earning Date | 05-13-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,043.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $1.02 |
| 52 Week High | $5.55 | $30.00 |
| Indicator | PYXS | DOGZ |
|---|---|---|
| Relative Strength Index (RSI) | 79.98 | 30.67 |
| Support Level | $1.28 | $1.02 |
| Resistance Level | $3.89 | $1.73 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 98.25 | 23.53 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.